TRAIL or Bay (a NF-κB inhibitor) treatment successfully curbed cell viability in drug-resistant gastric cancer cell lines, including SGC7901/DDP and BGC823/DDP (Fig. 3ai, bi), and the inhibitory effect was the most significant in TRAIL + Bay group. Here, NFKB1 is linked to gastric cancer.